Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects
Status:
Completed
Trial end date:
2020-02-06
Target enrollment:
Participant gender:
Summary
The study will enroll well-compensated cirrhotic as well as non-cirrhotic subjects treatment
experienced with an NS5a Inhibitor + sofosbuvir and will include patients who did not
complete the prescribed duration due to adverse event or any reason other than for non/poor
compliance. Subjects will be randomized to 12 or 16 weeks of treatment.